Aviso Financial Inc. lessened its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 26.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 17,047 shares of the medical equipment provider's stock after selling 6,093 shares during the quarter. Aviso Financial Inc.'s holdings in Boston Scientific were worth $1,523,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Parnassus Investments LLC increased its holdings in shares of Boston Scientific by 0.7% in the 4th quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider's stock worth $1,327,000 after buying an additional 97 shares during the last quarter. Adero Partners LLC increased its holdings in shares of Boston Scientific by 3.3% in the 4th quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock valued at $334,000 after acquiring an additional 120 shares during the period. Grove Bank & Trust boosted its position in Boston Scientific by 4.4% during the fourth quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider's stock valued at $261,000 after purchasing an additional 122 shares in the last quarter. PFG Investments LLC boosted its stake in Boston Scientific by 1.6% in the fourth quarter. PFG Investments LLC now owns 8,113 shares of the medical equipment provider's stock valued at $725,000 after acquiring an additional 125 shares in the last quarter. Finally, Stonegate Investment Group LLC boosted its position in shares of Boston Scientific by 1.6% in the 4th quarter. Stonegate Investment Group LLC now owns 7,827 shares of the medical equipment provider's stock worth $699,000 after purchasing an additional 126 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.
Boston Scientific Stock Performance
Boston Scientific stock traded up $0.27 during mid-day trading on Tuesday, reaching $99.17. 5,370,015 shares of the company were exchanged, compared to its average volume of 5,742,343. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The firm has a market cap of $146.36 billion, a PE ratio of 79.34, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. The firm's 50-day simple moving average is $101.21 and its two-hundred day simple moving average is $91.97. Boston Scientific Co. has a twelve month low of $66.16 and a twelve month high of $107.17.
Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.
Insider Activity
In other Boston Scientific news, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the transaction, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. The trade was a 10.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the sale, the executive vice president now directly owns 28,454 shares in the company, valued at $2,966,329.50. This trade represents a 14.11 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 137,302 shares of company stock worth $14,319,269. Company insiders own 0.50% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages have commented on BSX. Wells Fargo & Company lifted their price target on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. JPMorgan Chase & Co. upped their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a research report on Monday, December 16th. Stifel Nicolaus increased their price objective on Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research note on Friday, January 10th. Finally, Truist Financial raised their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of "Moderate Buy" and a consensus target price of $108.91.
Read Our Latest Stock Analysis on Boston Scientific
About Boston Scientific
(
Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Recommended Stories
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
